Alteogen Inc.
196170
Ранг среди акций
#1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Цена акции
$165.61
Рыночная капитализация
$11.53B
Изменение (1 день)
4.13%
Изменение (1 год)
-46.48%
Страна
KR
Торговля Alteogen Inc. (196170)
Категория
Healthcare
Прибыль Alteogen Inc. (196170)
Прибыль на Jun 2026 TTM: $149.40M
Согласно последним финансовым отчетам Alteogen Inc., текущая прибыль компании составляет $149.40M. В 2023 году компания получила прибыль $-2.75M, больше, чем прибыли за 2022, которая составила $-7.90M. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Alteogen Inc. с 2012 по 2026
Прибыль в конце каждого года
| Год | Прибыль | Изменить |
|---|---|---|
| 2026 (TTM) | $149.40M | 499.94% |
| 2024 | $24.90M | -1,004.44% |
| 2023 | $-2.75M | -65.15% |
| 2022 | $-7.90M | -12.17% |
| 2021 | $-9.00M | -44.80% |
| 2020 | $-16.30M | 1,019.63% |
| 2019 | $-1.46M | -73.14% |
| 2018 | $-5.42M | -21.67% |
| 2017 | $-6.92M | 87.17% |
| 2016 | $-3.70M | -514.99% |
| 2015 | $890.56K | 26.52% |
| 2014 | $703.88K | -54.02% |
| 2013 | $1.53M | 12.53% |
| 2012 | $1.36M | 0.00% |
Прибыль схожих компаний или конкурентов
| Компания | Прибыль | Разница в прибыли | Страна |
|---|---|---|---|
| $5.27B | 3,430.63% |
US
|
|
| $-3.09B | -2,166.21% |
US
|
|
| $-4.02B | -2,788.14% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,205.62% |
NL
|
